Literature DB >> 26104998

Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations.

Sietse M Aukema1,2,3, Laura Theil1, Marius Rohde4, Benedikt Bauer5, Jutta Bradtke6, Birgit Burkhardt7, Bettina R Bonn7, Alexander Claviez8, Stefan Gattenlöhner6, Olga Makarova7, Inga Nagel1, Ilske Oschlies9, Christiane Pott10, Monika Szczepanowski9, Arne Traulsen6, Philip M Kluin2, Wolfram Klapper9, Reiner Siebert1, Eva M Murga Penas1.   

Abstract

Typical Burkitt lymphoma is characterized by an IG-MYC translocation and overall low genomic complexity. Clinically, Burkitt lymphoma has a favourable prognosis with very few relapses. However, the few patients experiencing disease progression and/or relapse have a dismal outcome. Here we report cytogenetic findings of seven cases of Burkitt lymphoma in which sequential karyotyping was performed at time of diagnosis and/or disease progression/relapse(s). After case selection, karyotype re-review and additional molecular analyses were performed in six paediatric cases, treated in Berlin-Frankfurt-Münster-Non-Hodgkin lymphoma study group trials, and one additional adult patient. Moreover, we analysed 18 cases of Burkitt lymphoma from the Mitelman database in which sequential karyotyping was performed. Our findings show secondary karyotypes to have a significant increase in load of cytogenetic aberrations with a mean number of 2, 5 and 8 aberrations for primary, secondary and third investigations. Importantly, this increase in karyotype complexity seemed to result from recurrent secondary chromosomal changes involving mainly trisomy 21, gains of 1q and 7q, losses of 6q, 11q, 13q, and 17p. In addition, our findings indicate a linear clonal evolution to be the predominant manner of cytogenetic evolution. Our data may provide a biological framework for the dismal outcome of progressive and relapsing Burkitt lymphoma.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Burkitt lymphoma; MYC; clonal evolution; progression; relapse

Mesh:

Substances:

Year:  2015        PMID: 26104998     DOI: 10.1111/bjh.13501

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Diagnosis and classification of lymphoma: Impact of technical advances.

Authors:  Elaine S Jaffe
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

2.  Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.

Authors:  Sietse M Aukema; Giorgio A Croci; Reiner Siebert; Wolfram Klapper; Susanne Bens; Kathrin Oehl-Huber; Rabea Wagener; German Ott; Andreas Rosenwald; Philip M Kluin; Eva van den Berg; Anneke G Bosga-Bouwer; Mels Hoogendoorn; Eva Hoster; Iris Bittmann; Inga Nagel; Eva M Murga Penas; Markus Kreuz; Julia Bausinger; Wilfried Belder; Ilske Oschlies; Martin J S Dyer; Sandrine Jayne
Journal:  Virchows Arch       Date:  2021-02-02       Impact factor: 4.064

3.  5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.

Authors:  Fabian Müller; Tyler Cunningham; Stephanie Stookey; Chin-Hsien Tai; Sandra Burkett; Parthav Jailwala; Maryalice Stetler Stevenson; Margaret C Cam; Alan S Wayne; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-05       Impact factor: 11.205

4.  The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.

Authors:  Katrin S Hüttl; Annette M Staiger; Julia Richter; M Michaela Ott; Sabrina Kalmbach; Wolfram Klapper; Anne-Sophie Biesdorf; Lorenz Trümper; Andreas Rosenwald; Marita Ziepert; Heike Horn; German Ott
Journal:  Virchows Arch       Date:  2021-03-02       Impact factor: 4.064

5.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

6.  In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.

Authors:  Jessica Opie; Katherine Antel; Ania Koller; Nicolas Novitzky
Journal:  Ann Hematol       Date:  2020-01-18       Impact factor: 3.673

7.  Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations.

Authors:  Birgit Burkhardt; Mary Taj; Nathalie Garnier; Veronique Minard-Colin; Volkan Hazar; Karin Mellgren; Tomoo Osumi; Alina Fedorova; Natalia Myakova; Jaime Verdu-Amoros; Mara Andres; Edita Kabickova; Andishe Attarbaschi; Alan Kwok Shing Chiang; Eva Bubanska; Svetlana Donska; Lisa Lyngsie Hjalgrim; Jacek Wachowiak; Anna Pieczonka; Anne Uyttebroeck; Jelena Lazic; Jan Loeffen; Jochen Buechner; Felix Niggli; Monika Csoka; Gergely Krivan; Julia Palma; G A Amos Burke; Auke Beishuizen; Kristin Koeppen; Stephanie Mueller; Heidi Herbrueggen; Wilhelm Woessmann; Martin Zimmermann; Adriana Balduzzi; Marta Pillon
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 8.  Genetic background and evolution of relapses in aggressive B-cell lymphomas.

Authors:  Darius Juskevicius; Stephan Dirnhofer; Alexandar Tzankov
Journal:  Haematologica       Date:  2017-05-29       Impact factor: 9.941

9.  Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.

Authors:  Alexander M Newman; Masood Zaka; Peixun Zhou; Alex E Blain; Amy Erhorn; Amy Barnard; Rachel E Crossland; Sarah Wilkinson; Amir Enshaei; Julian De Zordi; Fiona Harding; Mary Taj; Katrina M Wood; Despina Televantou; Suzanne D Turner; G A Amos Burke; Christine J Harrison; Simon Bomken; Chris M Bacon; Vikki Rand
Journal:  Leukemia       Date:  2021-10-21       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.